See more : Kadant Inc. (KAI) Income Statement Analysis – Financial Results
Complete financial analysis of Item 9 Labs Corp. (INLB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Item 9 Labs Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Emera Incorporated (ERRAF) Income Statement Analysis – Financial Results
- Anoto Group AB (publ) (ANOT.ST) Income Statement Analysis – Financial Results
- Public Joint Stock Company “ROSSETI Northern Caucasus” (MRKK.ME) Income Statement Analysis – Financial Results
- Cheerwin Group Limited (6601.HK) Income Statement Analysis – Financial Results
- IIFL Securities Limited (IIFLSEC.NS) Income Statement Analysis – Financial Results
Item 9 Labs Corp. (INLB)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.item9labscorp.com
About Item 9 Labs Corp.
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.76M | 21.94M | 8.12M | 4.93M | 1.38M | 243.93K | 324.03K | 113.02K | 179.49K | 341.99K | 892.19K | 0.00 |
| Cost of Revenue | 14.45M | 13.32M | 4.83M | 2.56M | 1.02M | 80.68K | 158.32K | 117.31K | 115.66K | 143.82K | 417.78K | 0.00 |
| Gross Profit | 7.31M | 8.61M | 3.30M | 2.38M | 357.19K | 163.25K | 165.70K | -4.28K | 63.83K | 198.17K | 474.41K | 0.00 |
| Gross Profit Ratio | 33.61% | 39.26% | 40.58% | 48.19% | 25.97% | 66.93% | 51.14% | -3.79% | 35.56% | 57.95% | 53.17% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 17.02M | 9.89M | 5.52M | 4.12M | 394.40K | 157.49K | 729.38K | 869.65K | 962.16K | 1.31M | 4.10M | 23.11K |
| Selling & Marketing | 1.81M | 1.17M | 265.03K | 741.87K | 108.83K | 3.54K | 42.21K | 241.94K | 206.77K | 282.38K | 152.62K | 0.00 |
| SG&A | 18.83M | 11.06M | 5.79M | 4.86M | 503.23K | 161.04K | 771.59K | 1.11M | 1.17M | 1.59M | 4.26M | 23.11K |
| Other Expenses | 11.55M | 3.15M | 2.84M | 1.90M | 545.39K | -58.93K | 0.00 | -21.53K | -2.70K | -141.43K | 730.00 | 0.00 |
| Operating Expenses | 30.38M | 14.21M | 8.62M | 6.76M | 1.05M | 161.04K | 771.59K | 1.11M | 1.17M | 1.59M | 4.26M | 23.11K |
| Cost & Expenses | 44.82M | 27.54M | 13.45M | 9.32M | 2.07M | 241.72K | 929.91K | 1.23M | 1.28M | 1.74M | 4.67M | 23.11K |
| Interest Income | 0.00 | 5.30M | 6.96M | 71.38K | 29.86K | 0.00 | 0.00 | 0.00 | 289.00 | 0.00 | 3.02K | 0.00 |
| Interest Expense | 6.41M | 5.30M | 6.96M | 342.72K | 1.99K | 268.78K | 992.18K | 2.96M | 1.37M | 1.76M | 270.85K | 0.00 |
| Depreciation & Amortization | 1.92M | 1.26M | 979.16K | 676.13K | 49.79K | 17.31K | 9.93K | 64.48K | 65.75K | 62.96K | 60.95K | 0.00 |
| EBITDA | -22.83M | -4.35M | -4.45M | -8.93M | -604.03K | -164.21K | -2.12M | -1.72M | -15.65M | -1.50M | -3.76M | -23.11K |
| EBITDA Ratio | -104.93% | -19.83% | -53.52% | -64.27% | -44.48% | 2.34% | -183.92% | -949.31% | -580.38% | -1,247.07% | -416.66% | 0.00% |
| Operating Income | -23.07M | -5.60M | -5.33M | -4.38M | -691.43K | 2.21K | -605.89K | -1.12M | -1.11M | -1.39M | -3.78M | -23.11K |
| Operating Income Ratio | -106.01% | -25.53% | -65.58% | -88.82% | -50.28% | 0.91% | -186.99% | -987.31% | -615.67% | -407.78% | -423.83% | 0.00% |
| Total Other Income/Expenses | -8.10M | -5.30M | -6.96M | 192.40K | -9.74K | -268.78K | -2.52M | -3.62M | -15.98M | -1.93M | -306.34K | 0.00 |
| Income Before Tax | -31.17M | -10.91M | -12.39M | -9.95M | -663.56K | -266.57K | -3.13M | -4.74M | -17.08M | -3.33M | -4.09M | -23.11K |
| Income Before Tax Ratio | -143.25% | -49.71% | -152.50% | -201.64% | -48.25% | -109.28% | -964.59% | -4,194.48% | -9,516.88% | -972.27% | -458.17% | 0.00% |
| Income Tax Expense | 13.22K | 5.29M | -85.98K | 682.52K | 29.86K | -13.81K | 992.18K | 2.94M | 1.36M | 1.62M | -188.00K | 0.00 |
| Net Income | -31.14M | -16.19M | -12.30M | -10.63M | -642.28K | -266.57K | -3.13M | -4.74M | -17.08M | -3.33M | -4.09M | -23.11K |
| Net Income Ratio | -143.14% | -73.81% | -151.44% | -215.47% | -46.70% | -109.28% | -964.59% | -4,194.48% | -9,516.88% | -972.27% | -458.17% | 0.00% |
| EPS | -0.33 | -0.21 | -0.20 | -0.17 | -0.23 | -0.04 | -0.82 | -1.43 | -6.87 | -1.94 | -3.26 | -0.05 |
| EPS Diluted | -0.33 | -0.21 | -0.20 | -0.17 | -0.23 | -0.04 | -0.82 | -1.43 | -6.87 | -1.94 | -3.26 | -0.05 |
| Weighted Avg Shares Out | 95.69M | 78.59M | 61.62M | 61.53M | 2.74M | 7.46M | 3.81M | 3.32M | 2.49M | 1.72M | 1.25M | 445.50K |
| Weighted Avg Shares Out (Dil) | 95.69M | 78.59M | 61.62M | 61.53M | 2.74M | 7.46M | 3.81M | 3.32M | 2.49M | 1.72M | 1.25M | 445.50K |
Item 9 Labs Corp.'s (INLB) CEO Andrew Bowden on Q4 2021 Results - Earnings Call Transcript
Item 9 Labs Corp.'s (INLB) CEO Andrew Bowden on Q4 2021 Results - Earnings Call Transcript
Item 9 Labs Corp. to Acquire Colorado Dispensary, Kickstarts National Acquisition Growth Plan
PHOENIX, Oct. 7, 2021 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—today announced it has signed an Asset Purchase Agreement ("APA") for an existing dispensary license and...
Item 9 Labs Corp. Bolsters Marketing Team with Multiple Key Hires
PHOENIX, Oct. 4, 2021 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company"), a vertically integrated, cannabis dispensary franchisor and operator that produces premium, award-winning products, today announced that the Company has added a senior-level marketing executive and a mid-level marketing...
Unity Rd. Vice President and Franchise Partner to Present at MLive Cannabis Insights Event on October 7
DETROIT, Sept. 29, 2021 /PRNewswire/ -- Unity Rd.
Item 9 Labs Corp. to Present at A.G.P.'s Virtual Fall Consumer Cannabis Conference October 5
PHOENIX, Sept. 28, 2021 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—today announced it will participate in the A.G.P.
Unity Rd. Inks Deals for New Jersey and Virginia; Announces Maine Expansion
EDISON, N.J., Sept. 24, 2021 /PRNewswire/ -- Unity Rd.
Item 9 Labs Corp.'s Dispensary Franchise Expands NE Footprint into 2 New States
PHOENIX, Sept. 23, 2021 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated, cannabis dispensary franchisor and operator that produces premium, award-winning products—today announced continued development of its cannabis dispensary franchise brand, Unity Rd.
Item 9 Labs Corp. Secures $19 Million Construction-Financing Loan with Pelorus Equity Group for Expansion of Cultivation & Lab Sites in Arizona & Nevada
PHOENIX , Aug. 31, 2021 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the " Company") , a vertically integrated, cannabis dispensary franchisor and operator that produces premium, award-winning products, has entered into a $19 million construction-financing loan with Pelorus Equity Group ("Pelorus"),...
Item 9 Labs' Cannabis Cup Win Marks 9 Top Podium Placements
PHOENIX, Aug. 25, 2021 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company"), a vertically integrated, cannabis dispensary franchisor and operator that produces premium, award-winning products, today announced that it has earned two podium finishes in Arizona's first-ever High Times Cannabis...
Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q3 2021 Results - Earnings Call Transcript
Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q3 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports